For instance, in cancers marked by the overexpression of non-classical HLAs, like HLA-G or HLA-E, interventions aimed at blocking their interactions with immune receptors could potentially restore immune surveillance and amplify anti-tumor responses. The gene discussed is HLA-S; the disease is cancer.